Affirm Ramps Up Lending Firepower With $750M New York Life Deal and Worldpay Distribution as Q1 FY26 Results Arrive Today (Nov. 6)

6 November 2025

November 6, 2025 — Fintech & Payments | BNPL, AFRM, Worldpay, New York Life

Meta description (SEO): Affirm expands its long‑term capital partnership with New York Life and deepens distribution via Worldpay for Platforms—just hours before reporting Q1 FY26 earnings. Here’s what the deals mean for BNPL, merchants, and investors.

Key takeaways

$750 million forward‑flow from New York Life will see the insurer purchase Affirm installment loans through December 2026, providing off‑balance‑sheet funding that can support ~$1.75B in annual loan volume, per the companies. ^[1]
Worldpay for Platforms integration brings Affirm to 1,000+ SaaS platforms that processed $400B+ in payments and 4.6B transactions over the last 12 months—broadening merchant reach across vertical SaaS. ^[2]
Earnings today (Nov. 6): Affirm is scheduled to report Q1 FY2026 after the bell; Street previews point to roughly $0.10–$0.11 EPS on ~$882–$885M revenue. ^[3]
The moves arrive as Global Payments works to acquire Worldpay, reshaping processor dynamics that could further amplify distribution for embedded BNPL partners like Affirm. ^[4]
They also extend Affirm’s diversified capital stack, following earlier partnerships with Liberty Mutual Investments, PGIM, and Sixth Street. ^[5]

What’s new

Affirm × New York Life, expanded. Affirm said New York Life will buy Affirm’s consumer installment loans on a forward‑flow basis with up to $750M outstanding through Dec. 2026. The structure keeps loans off Affirm’s balance sheet and, by recycling capital, can support about $1.75B in yearly originations—extra capacity headed into peak holiday demand. New York Life has already invested nearly $2B in Affirm collateral via ABS and related structures, underscoring longstanding confidence in Affirm’s credit performance. ^[6]

Affirm × Worldpay, deeper distribution. A separate deal brings Affirm directly into Worldpay for Platforms, enabling platform providers to switch on Affirm at checkout for their merchants. Worldpay says the program spans 1,000+ SaaS platforms and $400B+ in processed volume over the past year; the integration aims to make offering Pay‑in‑4 and monthly installments (30 days up to 60 months; $35–$30,000 carts) as simple as a settings toggle. Quotes from both sides framed it as a friction‑reduction play for platform partners and their merchants. ^[7]

“Bulking up” ahead of earnings. Trade press captured the one‑two punch of a distribution deal plus fresh funding as part of Affirm’s pre‑earnings positioning this week. ^[8]

Why it matters

1) Capital efficiency & risk transfer.
Forward‑flow purchases from an insurer provide predictable liquidity without bloating the balance sheet—vital for BNPL lenders that scale loan volume through varying macro cycles. The New York Life line complements warehouse facilities and securitizations, keeping Affirm’s cost of funds diversified. ^[9]

2) Embedded distribution flywheel.
Worldpay’s platform reach puts Affirm where merchants already operate—inside their vertical SaaS. That can lower integration lift, broaden acceptance, and raise activation rates versus one‑off merchant integrations. ^[10]

3) Processor landscape in flux.
Worldpay’s pending acquisition by Global Payments (expected to close H1 2026) could expand Affirm’s indirect reach if combined merchant networks and tooling accelerate adoption of checkout alternatives like BNPL. ^[11]

By the numbers

$750M: Maximum outstanding balance New York Life will purchase under the forward‑flow through Dec. 2026. ^[12]
~$1.75B/yr: Origination capacity supported by the arrangement, due to loan recycling. ^[13]
1,000+ SaaS platforms | $400B+ volume | 4.6B transactions: Worldpay for Platforms scale over the past year. ^[14]
Earnings consensus: ~$0.10–$0.11 EPS; ~$882–$885M revenue for Q1 FY26 (today). ^[15]

Competitive context: BNPL’s capital arms race

Affirm’s insurer‑ and private‑credit partnerships mirror a broader BNPL trend: institutional buyers funding consumer receivables at scale. In September, PayPal announced a two‑year deal with Blue Owl to sell approximately $7B of U.S. Pay‑in‑4 loans, illustrating the sector’s shift toward committed, off‑balance‑sheet capital. ^[16]

Affirm, for its part, has previously extended its capital base with Liberty Mutual Investments (up to $750M program potential toward $5B) and PGIM Fixed Income ($500M), alongside a $4B investment framework with Sixth Street intended to underpin $20B in loans over three years. Together, these moves broaden funding sources and reduce dependency on any single channel. ^[17]

What to watch in today’s earnings (Nov. 6)

Funding costs & mix: How the New York Life forward‑flow and other facilities shape the blended cost of capital and margins this quarter. ^[18]
GMV & merchant distribution: Early signals from the Worldpay integration and other platform partnerships on activation and conversion uplift. ^[19]
Credit performance: Charge‑offs, delinquencies, and repeat‑use behavior—key to sustaining insurer and private‑credit appetite for Affirm assets. (Preview coverage highlights stable trends to date; details arrive with tonight’s results.) ^[20]
Affirm Card & app engagement: Management has emphasized distribution into direct channels; look for updates following October’s promotional calendar and partner launches ahead of holidays. ^[21]
Outlook into peak season: Guidance on GMV, revenue take rate, and unit economics as holiday shopping accelerates. ^[22]

Analyst & market setup

Previews heading into the print call for EPS around $0.10–$0.11 and revenue around $882–$885M, after a year of sizable beats and improving profitability traction. The after‑market call today will set the tone for the rest of the holiday quarter. ^[23]

Bottom line

On the very day it reports Q1 FY26 results, Affirm is pairing fresh capital with wider pipes. The New York Life expansion strengthens liquidity and capital efficiency; the Worldpay integration broadens distribution. Together, they tilt the company toward faster, lower‑friction growth—while the market waits to see if tonight’s numbers confirm profitability and credit discipline into the holidays. ^[24]

Sources & further reading

Business Wire: Affirm expands long‑term capital partnership with New York Life (details on $750M forward‑flow; ~$1.75B/yr capacity; prior ~$2B invested). ^[25]
Business Wire: Affirm expands partnership with Worldpay for Platforms (1,000+ SaaS, $400B+ volume, product details). ^[26]
American Banker: “Affirm bulks up lending power ahead of earnings” (context on deal timing and strategy). ^[27]
Yahoo Finance roundup on Affirm bulking up lending power (pre‑earnings context). ^[28]
Affirm IR: Earnings timing (Nov. 6, after market). ^[29]
Zacks & MarketBeat: Consensus previews for Q1 FY26. ^[30]
FT / AP: Global Payments to acquire Worldpay (sector backdrop). ^[31]
Reuters / WSJ: Liberty Mutual, PGIM capital partnerships (Affirm’s diversified funding). ^[32]
FT: Sixth Street framework to fund up to $20B in loans over three years. ^[33]
PayPal newsroom: Blue Owl to buy ~$7B Pay‑in‑4 receivables (BNPL capital market context). ^[34]

Disclosure: This article is for information only and is not investment advice.

If you got an AFFIRM LOAN Watch this‼️

Watch this video on YouTube.

References

Tags:

Marcin Frąckiewicz Latest posts

CEO of TS2 Space and founder of TS2.tech. Expert in satellites, telecommunications, and emerging technologies, covering trends in space, AI, and connectivity.

View all

Is Elevance Health a Hidden Opportunity After a 24.5% Drop in 2025?
November 6, 2025, 7:28 AM EST. Elevance Health has tumbled in 2025 amid policy shifts and broader healthcare-sector volatility, with a year-to-date drawdown and a longer 24.5% slide that has investors rethinking value. The piece weighs near- and long-term catalysts, noting that a high valuation score isn't translating into certainty as government program changes loom for managed care. The core takeaway is a rigorous DCF assessment, which, using current free cash flow of $3.6B and projected growth, yields an intrinsic value around $1,090.84 per share-roughly 71% above current prices, signaling undervaluation. Still, equity investors should monitor the PE ratio, competitive dynamics, and policy risk, which could affect how quickly this perceived bargain translates into realized gains.
Inflammation Biotech Evommune Starts NYSE Trading in $150M IPO
November 6, 2025, 7:24 AM EST. Evommune is heading to the NYSE with a $150 million IPO to fund two clinical-stage assets. The Palo Alto biopharma is offering 9.3 million shares at $16 each, pricing in the $15-$17 range. Gross proceeds are $150 million, potentially rising by about $22.5 million if underwriters exercise their option for an additional 1.4 million shares. Trading under the ticker EVMN could begin today. The company plans to use the funds to advance two phase 2 programs, including EVO756, an oral MRGPRX2 antagonist being studied for CSU and atopic dermatitis (AD). Topline data for CSU from a phase 2 study showed 93% responses at four weeks. Data for AD topline in H2 2026. Evommune priced amid a broader biotech IPO backdrop as MapLight Therapeutics went public last week.
Arm Holdings Stock Surges on Q2 Beat, Strong AI Demand Lifts Outlook
November 6, 2025, 7:22 AM EST. Arm Holdings (ARM) stock jumps about 5-6% in pre-market trading after reporting a Q2 beat that topped revenue and earnings estimates and issuing stronger Q3 guidance. The company posted revenue of $1.14 billion, up 34% year over year, and EPS of $0.22, exceeds consensus of $0.13. Arm also raised its quarterly revenue guide to about $1.23 billion versus the $1.10 billion expected. Royalty revenue reached a record $620 million, up 21%, led by data centers, automotive, and IoT, with hyperscalers like Google, Amazon, and Microsoft boosting Arm-based deployments. Licensing revenue rose 56% to $515 million. The AI infrastructure buildout underscores demand for Arm's energy-efficient designs, and management hints at potential in-house chip development beyond licensing.
Capital One Stock Prediction: Analysts See Up to 29% Upside by 2027 on Discover Acquisition
November 6, 2025, 7:20 AM EST. Capital One (NYSE: COF) trades around $221 with an average target near $260, implying ~18% upside. Targets span $290 (high) and $210 (low), with a median near $258 and a mix of 14 Buys, 3 Outperforms, and 6 Holds. Growth projections call for revenue up about 19% annually through 2027, supported by operating margins near 48% and a forward multiple around 9.7x. A guided model points to ~$285/share by 2027, or about 29% total upside (12% annualized). The story centers on the Discover acquisition, expanded payments network, and stable credit trends amid solid consumer spending, though conviction remains modest and upside depends on continued earnings growth and credit stability.
Three Stocks Added to Zacks Rank #5 Strong Sell List on Nov. 6: ACHC, FWRD, CENX
November 6, 2025, 7:18 AM EST. Three names were added to Zacks Rank #5 (Strong Sell) today: Acadia Healthcare (ACHC), Forward Air (FWRD), and Century Aluminum (CENX). For the current year, earnings estimates were revised downward by 3.2%, 12%, and 11.7% over the last 60 days, respectively. The update reinforces the Strong Sell roster per Zacks research. The piece also highlights a separate feature on a stock most likely to double and a prompt to download Zacks' top stock ideas.